All In Biotech

Drug Trial Radar · NCT03092102

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Last checked: Nov 19, 2026Latest source record: Jul 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

May 20, 2017

Primary completion

Feb 25, 2019

Study completion Feb 25, 2019

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • HEC585Drug

    HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
  2. (AUC0-∞)Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h
  3. tmaxTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
  4. Vz/FTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h
  5. t½Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
  6. CL/FTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit, Inc.

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.